文献速递湿疹皮炎与荨麻疹

特应性皮炎临床试验中纳入标准与基线严重度评估的异质性:系统综述

Severity assessments used for inclusion criteria and baseline severity evaluation in atopic dermatitis clinical trials: a systematic review.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-09-14

该系统综述纳入2007至2016年212项特应性皮炎药物干预随机对照试验,发现目标人群和基于严重度的纳入标准分别有36.8%和18.7%的研究未记录。

要点

  • 212项特应性皮炎随机对照试验中,36.8%未记录目标人群,18.7%未记录基于严重度的纳入标准。
  • 北美常用整体评估,欧洲和亚洲常用SCORAD或客观SCORAD,IGA多用于外用药物试验。

核心结论

  • 特应性皮炎随机对照试验的纳入标准和基线严重度评估存在显著异质性且记录不充分,可能限制研究解读和结果比较。

研究设计与样本

  • 系统综述纳入2007至2016年发表的药物干预随机对照试验,检索Cochrane Library、EMBASE、GREAT、LILACS、MEDLINE和Scopus,由两名作者独立筛选和提取数据,共纳入212项试验。

主要发现

  • 212项试验中,78项(36.8%)未记录目标人群,25项(18.7%)未记录基于特应性皮炎严重度的纳入标准。
  • 北美最常用整体评估作为纳入标准(39.5%)和基线评估(32.1%),欧洲最常用SCORAD或客观SCORAD(23.5%和23.0%),亚洲最常用SCORAD或客观SCORAD(34.2%和43.5%)。
  • SCORAD、整体评估和体表面积是纳入标准和基线评估中最常用的工具,IGA特别用于外用药物试验。
  • 即使目标人群相似,不同研究对严重度评估的最小和最大阈值使用也不一致。

关键数值与推荐

  • 纳入标准最常用SCORAD、整体评估和体表面积,基线严重度评估最常用SCORAD、整体评估和体表面积。
  • 北美纳入标准和基线评估最常用整体评估(39.5%和32.1%),欧洲最常用SCORAD或客观SCORAD(23.5%和23.0%),亚洲最常用SCORAD或客观SCORAD(34.2%和43.5%)。
  • IGA特别用于外用药物试验。

临床怎么用

  • 解读特应性皮炎临床试验结果时需注意纳入标准和基线严重度评估工具的差异,避免直接比较不同研究的结果。
  • 设计新试验时应明确记录目标人群和基于严重度的纳入标准,并考虑采用共识推荐的评估工具以提高可比性。

局限性

  • 仅纳入2007至2016年发表的药物干预随机对照试验,未涵盖非药物干预或更近期研究。
  • 未评估异质性对治疗效应估计的具体影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Numerous inclusion criteria and baseline severity assessments are used in clinical trials of atopic dermatitis (AD), which may limit comparison of results. OBJECTIVE: We sought to characterize the inclusion criteria and baseline severity assessments used in randomized controlled trials (RCT) of AD internationally. METHODS: We performed a systematic review of RCT with a pharmacological intervention from 2007 to 2016. Cochrane Library, EMBASE, GREAT, LILACS, MEDLINE and Scopus were searched. Two authors independently performed study selection and data extraction. RESULTS: Overall, 212 RCT met inclusion/exclusion criteria. Target population and inclusion criteria based on AD severity were not documented in 78 (36.8%) and 25 (18.7%) studies, respectively. Thirty and 58 severity assessments were used for inclusion criteria and baseline severity, respectively, with only 60.3% concordance between their uses. Global assessments were most frequently used for both inclusion criteria and baseline severity assessment in North America (39.5% and 32.1%), while SCORing AD (SCORAD) or objective-SCORAD index was most frequently used in Europe (23.5% and 23.0%) and Asia (34.2% and 43.5%). Minimum and maximum thresholds of severity assessments were inconsistently used between studies for inclusion criteria, even within similar target populations. SCORAD, global assessments and body surface area were most frequently used for both inclusion criteria and baseline severity assessment. IGA was particularly used in trials of topical agents. CONCLUSIONS: There were considerable variability and poor documentation of inclusion criteria and baseline severity assessments in RCT for AD. These differences may limit interpretation of a study and comparison of results between studies.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Chopra R, Vakharia PP, Simpson EL, et al. Severity assessments used for inclusion criteria and baseline severity evaluation in atopic dermatitis clinical trials: a systematic review. J Eur Acad Dermatol Venereol. 2017. PMID: 28750145. doi:10.1111/jdv.14483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。